STUDY QUESTION: What are the consequences of radioactive iodine (RAI) therapy for testicular function?
Introduction
Differentiated thyroid carcinoma (DTC) is one of the most prevalent solid tumors in the world, affecting adults at any age. The incidence of DTC has increased since the early 1990s, although its mortality has remained stable (Davies and Welch, 2014) . DTC is classified into TNM stages I-V, according to the American Joint Comittee on Cancer (AJCC) staging protocol for DTC (Brierley et al., 2017) . Most young patients belong to DTC stage I associated with a good prognosis (Orosco et al., 2015) . On average their life expectancy is similar to that of the general population (Davies and Welch, 2014) and therefore, male patients with DTC are most likely to father children. The conventional therapeutic approach for DTC includes surgery and, according to the tumor stage, administration of radioactive iodine (RAI) to ablate remnant thyroid tissue, as well as to decrease the risk of recurrence (Haugen et al., 2016) . Generally, a single treatment of RAI corresponds to an activity of 1.1-3.7 GBq.
Germinal cells are known to be very sensitive to radiation at all stages of maturation (Ash, 1980) . The radiation dose delivered to the testes depends on the activity of 131 I administrated and the number of treatments (Ceccarelli et al., 1999) . Few studies have reported the potential impact of RAI on both endocrine and exocrine testicular function. Most were retrospective or longitudinal studies and designed to evaluate the impact of cumulative activities of 131 I, given over several years, by measuring testosterone, FSH and, to a lesser extent, inhibin B serum levels and sperm number (Pacini et al., 1994; Wichers et al., 2000; Hyer et al., 2002; Sawka et al., 2008; Canale et al., 2015) . However, current clinical practice recommends sperm banking only for cumulative activities, exceeding 14 GBq, as the latter have been shown to induce oligospermia (Haugen et al., 2016) .
Here, we designed a longitudinal prospective multi-center study (PHRC No. P040419) in patients with DTC (Clinical Trials.gov identifier NCT01150318). Hormonal levels, sperm number, as well as DNA fragmentation and sperm chromosomal abnormalities, have been measured before and after a single ablative activity of 3.7 GBq 131 I. Our major goal was to improve counseling of patients, concerning their potential fertility, when treatment with RAI is indicated.
Materials and Methods

Patients
This prospective study was carried out in five hospitals, all tertiary referral centers (University Hospital: Saint Antoine, Saint Louis, Pitié-Salpêtrière, Cancer Institute: Gustave Roussy, René Huguenin 
Inclusion and exclusion criteria
Male DTC patients, aged 18-55 years were included, if they had to be treated with 131 I. After thyroidectomy, they received thyroid hormone (Levothyroxine) at a daily dose of 2 μg/kg. This treatment was withdrawn 3-4 weeks before RAI administration and resumed after RAI, as recommended (Haugen et al., 2016) . A single activity of 3.7 GBq of 131 I was administered three months after surgery. All patients were hypothyroid with elevated TSH, to favor 131 I uptake, as indicated in Fig. 1 . They were admitted in nuclear medicine departments for 4 days. Two thermoluminescent dosimeters were positioned on each thigh, in the periscrotal region, for 4 days, just after RAI administration, in order to measure the radiation dose of 131 I, received by the testes.
All patients had a total body scan before being released from the hospital. Exclusion criteria were a previous history of radiotherapy and/or chemotherapy, azoospermia, a previous history of orchitis, fever, antibiotic and anti-inflammatory treatments within the past year. A testosterone baseline serum level below 2 ng/mL, based on the Endocrine Society Clinical guideline on androgen deficiency, was an exclusion criterium (Bhasin et al., 2010) . Informed consent was obtained from all patients.
In the initial design of the study, a control group included patients with a thyroid cancer and very low risk of recurrence, requiring only thyroidectomy without subsequent RAI. However, less than five patients had been included within the first year. The patient's refusals were essentially based on the burden to perform three sperm analysis and three blood analysis. Therefore, it was decided that the patients included in the study would be their own control.
Timing of the study
Hormonal evaluation, sperm analysis, fluorescent in situ hybridization (FISH) and DNA fragmentation were performed 6 weeks after surgery, before RAI (V0 = baseline), at 3 months (V3) and 13 months after treatment (V13) (Fig. 1) .
Hormonal parameters
All hormonal measurements were centralized and measured in a single laboratory. Serum FSH, LH and prolactin were measured with a fluorescent and chemiluminescent immunometric assay (Kryptor ® , Thermo Scientific B.R.A.H.M.S., Hennigsdorf, Germany), with a minimal detection (MDC) of 0.1 UI/L for FSH and LH and 0.2 ng/mL (4.2 mUI/L) for PRL. The intra-and inter-assay coefficients of variation were respectively 5.4 and 6.5% for FSH (3.4 UI/L), 5 and 7% for LH (3 UI/L) and 3.5 and 3.7%, for a PRL (5.7 ng/mL: 120 mUI/L). Thyroid stimulating hormone (TSH) was measured using a solid phase chemiluminescent immunocytometric assay (Immulite ® , Siemens Health Diagnostic Products Llanberis, UK.), MDC: 0.004 mUI/L. The intra-and inter-assay coefficients of variation were respectively 3.8 and 4.6% at 1.3 mUI/L.
Testosterone was assessed by a radioimmunoassay (RIA) method (Spectria ® Orion Diagnostica, Espoo, Finland: MDC: 0.02 ng/mL, 0.06 nmol/L), highly correlated with gas chromatography/mass spectrometry method (r = 0.95) (12). The intra-and inter-assay coefficients of variation were respectively 3.8 and 4.8% for a concentration of 3.2 ng/mL (11.4 nmol/L) and 4.8 and 5.5% for concentration of 6.7 ng/mL (23.3 nmol/L). Inhibin B was determined with a commercial ELISA (Serotec ® , Kidlington, Oxford, UK), MDC: 10 pg/mL and inter-and intra-assay coefficients of variation of 15 and 6%, respectively, for a concentration of 100 pg/mL (14).
Sperm parameters
Semen was collected after an abstinence interval of 2-5 days and analyzed according to WHO criteria (2010) at V0, V3 and V13, in a single laboratory. The assessed parameters were all performed on fresh sperm. Those included volume of ejaculate, sperm concentration and progressive motility, calculated as the percentage of spermatozoa displaying a progressive movement, vitality and morphology according to Auger et al. (2016) . The total sperm count was obtained by multiplying the number of spermatozoa/mL by the volume of ejaculate. Normal values were according to WHO standards (Cooper et al., 2010) . Sperm samples obtained before RAI were frozen and cryopreserved, for fertility preservation.
Sperm DNA fragmentation and sperm chromosomal abnormalities
In order to analyze possible effects on sperm nuclear content, both DNA fragmentation and chromosomal abnormalities were tested (Dere et al., 2013) . Sperm DNA fragmentation was detected with the terminal uridine nick-end labeling (TUNEL) technique (Roche Applied Science ® , Meylan, France) (Dupont et al., 2013) . In total, 500 spermatozoa per patient were examined by epifluorescence microscopy (Leica ® , Wetzlar, Germany). Total DNA fragmentation levels were calculated as the number of fluorescein-labeled nuclei divided by the total number of sperm nuclei. A percentage of DNA fragmentation higher than 14% was considered as abnormal (Dupont et al., 2013) . Chromosomal abnormalities were tested with of two sets of probes, corresponding, respectively, to chromosomes 13 (LSI-13q14, Spectrum Green) and 21 (LSI-21q22. 13-q22.2, Spectrum Orange) and the second one to chromosomes X (CEPX, DXZ1, Spectrum Green), Y (CEP Y, DYZ3 Spectrum Orange) and 18 (CEP 18, D18Z1 Spectrum Aqua). These chromosomes are the most often involved in disomies in sperm karyotypes from healthy men (Templado et al., 2013) . All probes were purchased from Vysis-Abbott ® , Downers Figure 1 Timing of the study, RAI = radioactive iodine. Immediately after thyroidectomy, patients receive thyroid hormones. They are euthyroid when sperm and blood analysis are performed at baseline (V0). Just after V0, thyroid hormonal replacement therapy is stopped, for 4 weeks duration, in order to enhance TSH levels and therefore iodine uptake. RAI is performed. Just after the treatment in nuclear medicine department, thyroid hormone treatment is resumed.
Grove, IL, USA. (Rives et al., 2017) . One thousand spermatozoa per patient were examined. The total percentage of chromosomal abnormalities per patient was calculated by extrapolating the data obtained from these 5 chromosomes to the 23 chromosomes of the human karyotype.
Radiation doses delivered to the testes
The dose of γ irradiation delivered to the testes was measured, as described previously (Ceccarelli et al., 1999) . The thermoluminescent dosimeters were analyzed at the Institute of Radioprotection and Nuclear Safety (IRSN) at Fontenay-aux-Roses, France.
Statistical analysis
Individual data were summarized using descriptive statistics: count and percent for qualitative variables, median and lower and upper quartiles (Q1 and Q3, respectively) or interquartile range (IQR), which is the difference between upper and lower quartiles for quantitative variables. Chi-square and Mann-Whitney-Wilcoxon tests were performed to identify differences between patients with complete and incomplete follow-up for qualitative and quantitative variables, respectively.
In this analysis, patients served as their own controls. McNemar's Test and Wilcoxon signed rank-sum tests were used to identify differences between the three times of measurement: before RAI administration, 3 and 13 months after treatment. These tests were used for evaluating the variation of qualitative and quantitative parameters, respectively. The Spearman's rank and Pearson correlation coefficient were applied to assess the rank values between variables at each of the measurements. Statistical analysis was performed using the SAS version 9.4 System (Cary, NC, USA). For all analyses, the 0.05 level of significance was used.
Results
A total of forty male patients were included in the study. Their characteristics are shown in Table I . Their median age was 34 years [interquartile range (IQR) = 12] and their BMI was 24 kg/m 2 (IQR = 5.3).
All included patients had normal thyroid and testicular function prior to RAI (V0), with a median TSH serum level of 2 mIU/L (IQR = 4.1) (N: 0.4-4 mIU/L), with a median testosterone serum level of 4.6 ng/mL (IQR = 2.4) (N: 3.5-8.5 ng/mL). At V0, median sperm concentration was 47 million/mL (IQR = 142) (N > 15 million/mL) (Table II) . Only two patients had oligospermia, respectively 8.4 and 6 million/mL (Fig. 3) . Overall, 19 patients (48%) had fathered prior to the study. Two patients had cryptorchidism, surgically corrected in infancy.
As indicated in the flow chart, the number of patients was 36 at V3 and 34 at V13 (Fig. 2) . One patient was excluded from the study after V3 because a second RAI administration was needed. In all remaining patients, DTC was classified as AJCC stage I (2). The median time between RAI and V3 was 87 days (IQR = 43) and 390 days (IQR = 47) between RAI and V13.
Data concerning testicular radiation dose was available for 23 patients. The mean dose absorbed by the testis was 74 ± 24 mSv. The remaining patients refused to carry the four thermoluminescent dosimeters, during the 4 days after RAI.
Among the included patients, 24 had completed the follow-up (V0, V3, V13). They had performed hormonal and sperm analysis at all three time points and were therefore included in the final statistical analysis. Their baseline characteristics were similar to those of the cohort studied (Table I) .
Variations in hormonal and sperm parameters between V0, V3 and V13 are reported in Table II for all patients and in Table III for the patients with complete follow-up. Serum prolactin levels were stable at all times. TSH levels were just below the normal range and were within the target values for DTC follow-up. LH median levels and the testosterone/LH ratio did not differ significantly between V0-V3 and V0-V13. However, testosterone/LH ratio decreased significantly between V3 and V13 (P = 0.02). FSH median levels significantly increased at V3 above the normal values as compared to those at V0 [[8.7 UI/L (IQR 6.1)] versus [3.8 UI/I, (IQR 3.3)], P < 0.0001]. Between V3 and V13, FSH levels decreased, but remained above baseline levels [5.7 UI/L (IQR = 3.2), P < 0.0001]. Median inhibin B serum levels decreased significantly at V3 (P < 0.0001) and were higher at V13 as compared to V0 (P < 0.02) (Fig. 3) . A negative correlation between FSH and inhibin B serum levels was observed at V3 (Pearson correlation coefficient = 0.72, P = 0.0001, Supplementary Fig. S1 ).
Median sperm concentration significantly decreased at V3 as compared to V0 [20 millions/mL (IQR = 28) versus 52 millions/mL (IQR = 142), P < 0.0001], but returned to baseline levels at V13. Eight patients (33%) went from normospermia at V0 to oligospermia at V3. At V3, a negative correlation was observed between FSH levels and sperm concentration (Pearson correlation coefficient = 0.44, P = 0.03, Supplementary Fig. S1 ). Accordingly, a positive correlation between inhibin B levels and sperm concentration was noted (Pearson correlation coefficient = 0.45 P = 0.03, Supplemental Fig. S1 ). In parallel, a statistically significant decrease in sperm morphologically normal forms was observed at V3, as compared to V0 [18% (IQR = 15) versus 28% (IQR = 15), P < 0.0001], which returned to normal levels at V13. Sperm motility was similar at all time points. DNA fragmentation was not modified after RAI administration. However, the frequency of sperm chromosomal abnormalities (disomies or aneuploidies) increased from 3.2% (IQR = 1.84) at baseline to 4.8% [(IQR = 2.76), P < 0.001] and 3.7% [(IQR = 1.38), P < 0.01] at V3 and V13, respectively.
Discussion
Current practice for the treatment of DTC involves the administration of RAI to patients with a significant risk of recurrence or thyroid cancer related death, in order to obtain a high ablation success rate and the eradication of micro-metastasis (Hackshaw et al., 2007) . Our study is the first that prospectively evaluates the effect of a single activity of 3.7 GBq of 131 I, in men with DTC that are rendered hypothyroid following surgery and have temporarily withdrawn thyroxine treatment, on hormonal levels, sperm parameters, sperm chromosomal abnormalities and DNA fragmentation in a cohort of male patients with stage 1 DTC, the most common form of DCT.
In this study, we show for a large number of patients that the mean dose absorbed by the testis was 74 ± 24 mSv, following the administration of a single activity of 3.7 GBq 131 I. This result is in agreement with the medical internal radiation dose (MIRD) reference value (Snyder et al., 1975 Figure 2 Flow Chart of patient inclusion and follow-up after radioactive iodine administration (RAI). V0: Inclusion of 40 patients: hormonal and sperm parameters analyses performed one month before RAI (baseline levels). Analysis of hormonal and sperm parameters was performed 3 months (V3) and 13 months (V13) after the administration of RAI. The four and six patients that had missed the evalution at V3 and V13, respectively, are not the same patients. In fine 24 patients have completed the entire follow-up.
We observed a statistically significant increase in FSH levels and a decrease in inhibin B levels, 3 months after RAI administration. Sperm concentration, as well as the percentage of morphologically normal spermatozoa, was statistically significantly decreased at V3 (P < 0.0001). These modifications were transient as both sperm concentration and normal morphology rate returned to baseline values at V13. Normal spermatogenesis needs functional Sertoli cells, stimulated by the pituitary hormone FSH, as well as sufficient testosterone production by Leydig cells (Huhtaniemi, 2015; Griswold, 2016) . Sertoli cells are considered as the main inhibin B-secreting cells in the testis (Meachem et al., 2001) . Inhibin production is dependent on the action of FSH and exerts a negative regulatory feedback on FSH secretion. Indeed, in normospermic males a negative correlation has been observed between inhibin B and FSH serum levels (Myers et al., 2009) . Moreover, in both fertile and infertile males, a positive correlation between inhibin B levels and sperm count has been reported (Barbotin et al., 2015) . Therefore, the measurement of both inhibin B and FSH serum levels serves as a reliable indicator of male spermatogenesis and potential fecundity. In the literature, several studies have dealt with the effects of 131 I on testicular function (review in Sawka et al., 2008) , although statistical analysis of the data was performed in only a few (Wichers et al., 2000; Rosário et al., 2006; Canale et al., 2015) . These different studies reported effects after single and/or cumulative activities of RAI ranging from 1.1 to 32 GBq. Wichers et al. (2000) and Rosario et al. (2006) reported a transient increase of FSH serum levels and a concomitant decrease in inhibin B serum levels, 2-6 months after a single activity of 3.7-5.5 GBq RAI. In addition, a transient increase in LH serum levels was noted in few patients who had received the highest activities, however, without any notable impact on testosterone levels. Some of the patients with metastasis had cumulative activities of 131 I, up to 14 GBq, resulting in persistent high FSH levels (>20 IU/L). LH serum levels also increased but without any significant impact on testosterone levels (Pacini et al., 1994) . More recently, Canale et al. (2015) reported prospectively a small cohort of 20 patients divided into two groups. Half of the patients were treated with a single ablative activity of 1.1 GBq of 131 I and the other half with high cumulative activities, ranging from 4.8 to 32 GBq. In the 1.1 GBq group, no variation of hormonal and sperm parameters was observed. In the group receiving cumulative doses, a permanent increase in serum FSH levels was noticed (Wichers et al., 2000; Rosário et al., 2006) . Therefore, cumulative doses of irradiation seem to have a deleterious effect on FSH levels. However, testosterone levels remained unaltered.
Our results show a clear transient alteration of gonadal function, mainly in Sertoli cell function at V3 and a progressive return to baseline levels at V13. This return is likely to be the consequence of concomitant increase in FSH levels. Concerning Leydig cell function, in the general male population a decrease of the testosterone/LH ratio defines a compensated functional failure of these cells, mainly linked to an increased LH concentration associated with a normal testosterone concentration (Jørgensen et al., 2016) . No impact on the testosterone/LH ratio was observed between V0-V3 and V0-V13.
It is of note that in the male population we studied, hormonal and sperm parameters at baseline were close to those of the general population (Cooper et al., 2010) . Furthermore, other causes of sperm alterations have been excluded: none of the patients presented hypogonadism since their testosterone levels were stable throughout the study. All patients had been treated with L-thyroxine resulting in serum TSH levels, within the normal range. Therefore, hypothyroidism, thyrotoxicosis (Krassas et al., 2010) , as well as hyperprolactinemia (Bernard et al., 2015) , known to impact on the gonadotrophic axis and, consequently, sperm characteristics, were absent (Tables II and  III) . Considering the effects of RAI on DNA fragmentation, only a single case has been previously reported after the administration of a single activity of 5.5 GBq 131 I. In this patient, sperm fragmentation was observed 3 months after RAI administration (Esquerré-Lamare et al., 2015) . In contrast, we report an absence of DNA fragmentation at V3 and V13, suggesting that a single dose of 3.7 GBq 131 I does not induce sperm apoptosis. To our knowledge, our study is the first to evaluate DNA fragmentation, as well as sperm aneuploidy, before and after RAI.
Concerning sperm chromosomal abnormalities, our study revealed a statistically significant increase both at V3 (P < 0.001) and V13 (P = 0.01). The sperm chromosomal abnormalities observed represent either disomy or aneuploidy. Fertilization with such spermatozoa may lead to chromosomally abnormal embryos (Chatziparasidou et al., 2015) . According to the viability of each aneuploidy, these embryos may lead to newborns with an abnormal karyotype or result in a miscarriage. In the sperm of healthy donors, the rate of aneuploidy is around 2.3%, which is lower than that observed (3.2%) at baseline in the population studied here (Templado et al., 2011 (Templado et al., , 2013 ). The few previously published studies that have evaluated sperm chromosomal abnormalities in male patients with cancer did focus on patients with lymphoma (Martinez et al., 2017) or testicular cancer (Rives et al., 2017) . In patients with cancer, increased sperm abnormalities were detected not only 3-12 months after, but also prior to, chemotherapy and/or radiotherapy (Tempest et al., 2008; Martinez et al., 2017) . These findings suggest that this type of cancer may by itself cause an increase in sperm chromosomal abnormalities. However, for thyroid cancer this causality has not been demonstrated. In the study by Rives et al., X, Y and 18 chromosomes have been tested in sperms from males with a testicular cancer. At baseline, before chemotherapy, aneuploidy was the most frequent abnormality. The percentage of sperms affected was 5.3%. At 3 months, the percentage of abnormalities increased to 13% and then decreased at 12 months to 6.4%. In the study by Martinez et al., the same set of chromosomes has been tested (X, Y and 18), in sperm from males with lymphoma. At baseline, before chemotherapy, disomy was the most frequent abnormality. The percentage of sperms affected was 5.6%. The percentage increased to 16.4% at 3 months and then decreased to 6.3% at 13 months. Therefore, the kinetic of abnormalities is similar to our study. Using a single activity of 3.7 GBq 131 I, an almost twofold increase in sperm chromosomal abnormalities was observed at V3 as compared to V0, followed by a progressive decrease at V13 between at levels that remained significantly higher than those at baseline. The exact consequences, associated with such an increase in sperm abnormalities are currently not well identified. However, it is to be stressed that, even if published studies including male and female patients treated with RAI for thyroid carcinoma have reported no decrease in fecundity and healthy offspring (Dottorini et al., 1995; Hyer et al., 2002) , studies in mice have clearly shown that the frequency of inherited germline mutations is significantly elevated in the offspring of male mice that were given whole-body acute irradiation of 3 Gy (Adewoye et al., 2015) . Therefore, a risk of elevated RAI activity on fertility as a result of inherited susceptibility to radiation-induced germline mutations in human cannot be excluded. Our study has several limitations. Only 24 patients had hormonal and sperm analysis at all three time points and were therefore included in the final statistical analysis. However, the baseline clinical and hormonal characteristics of the patients are similar to those of the entire cohort. Furthermore, our study is prospective and has included, to our knowledge, the largest number of patients, with hormonal as well as sperms parameters at all time points. The lack of correction for multiple comparisons with respect to the evolution of these parameters (Table III) could also be considered as a limitation. A final limitation may concern 131 I activity. Since 2012, the use of low activities of 131 I
(1.1 GBq) is recommended in low-risk DTC for post-operative ablation (Schlumberger et al., 2012) . However, patients may receive cumulative doses and patients with high-risk DTC are still treated with 3.7 GBq. In summary, our study illustrates the fact that treatment with 3.7 GBq responsible for a mean dose of 74 mSv absorbed by the testis, induced a transient alteration of the quality of male spermatogenesis three months after treatment and, as a consequence, a potential alteration of fertility that persists for at least 1 year. However, current clinical practice recommends sperm banking only for cumulative activities exceeding 14 GBq, as they have shown to induce oligospermia (Haugen et al., 2016) . In this respect, a dose of 3.7 GBq might be considered as a threshold value starting from which alterations of hormone levels and sperm parameters might be observed. Considering the duration of spermatogenesis and because of remaining sperm chromosomal abnormalities, patients could be counseled to avoid pregnancy in the first year following the administration of 3.7 GBq 131 I.
Conclusion
In our prospective study, we illustrate that the post-operative administration of a single activity of 3.7 GBq 131 I, may induce an alteration of Sertoli cells and sperm quality. Furthermore, the percentage of chromosomal abnormalities nearly doubles between baseline and V3 and persists at V13. Our results reinforce the new ATA (American Thyroïd Association) recommendations of selective use of postoperative RAI in low-risk DTC patients and where indicated the use of low activities of radioiodine following injections of recombinant TSH (Remy et al. 2008; Haugen et al. 2016) . Prospective studies with longer term follow up would be helpful to determine whether the chromosome abnormalities persist. These studies would be required before sperm banking should be suggested for all patients. Studies investigating the effects of the sperm abnormalities, potential impact of chromosomal abnormalities on the offspring and probability of radiation-induced germline mutations should be evaluated. However, testing male patient's fertility in a prospective study, after RAI may not be feasible, for ethical reasons. In the meantime, it seems reasonable to propose sperm banking for activities higher than 3.7 GBq that may be administered to high-risk DTC patients.
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